Retina

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.

Survey reveals severe impact of Good Days underfunding on retina practices, with many patients experiencing vision loss due to delayed access to care.

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

Optomed Lumo launches a versatile handheld fundus camera, enhancing retinal imaging accessibility in diverse healthcare settings across the US.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

The Eye Care Network connected with Haller to hear her vision for Wills Eye Hospital, her priorities as CEO, and what lies ahead for the field of ophthalmology.

Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.

Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

MCO-010 is a gene-agnostic therapy for retinitis pigmentosa.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.